SPPI News and Press, Spectrum Pharmaceuticals Inc. From 09/18/21

Early data from Cohort 4 of the ongoing ZENITH20 clinical trial shows ORR of 44% in 48 first-line patients treated with 16mg of poziotinib once daily Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology thera...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small cell lung cancer (NSCLC) with HER2 exo...

Boston, Massachusetts--(Newsfile Corp. - September 1, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who purchased shares and have lost money are encourage...

BOSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who have lost money in their Spectrum Pharmaceuticals investment should contact the firm to learn more abou...

Image source: The Motley Fool. Spectrum Pharmaceuticals, inc (NASDAQ: SPPI) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Spectrum Pharmaceuticals, inc (SPPI) Q2 2021 Earnings Call Tr...

Spectrum Pharmaceuticals, Inc. (SPPI) Q2 2021 Results Conference Call August 12, 2021 4:30 PM ET Company Participants Joe Turgeon – President and Chief Executive Officer Kurt Gustafson – Chief Financial Officer Francois Lebel – Chief Medical Officer Conference Call Partic...

Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation The company is requesting a meeting with the FDA to clarify the remediation timelines regarding the Complete Response Letter (CRL) for ROLONTIS ® (eflapegrastim) Management ...

SPPI received a surprise CRL for rolontis. This could be resolved before the year is out, but there is no real clarity. The company does have enough cash to last it for a year or more. For further details see: Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity ...

Gainers: Kaixin (NASDAQ:KXIN) +50%. Sphere 3D (NASDAQ:ANY) +42%. Westport Fuel Systems (NASDAQ:WPRT) +25%. SCWorx (NASDAQ:WORX) +24%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +22%. LiveRamp Holdings (NYSE:RAMP) +20%. Grid Dynamics (NASDAQ:GDYN) +19%. Bit Digital (NASDAQ:BTBT) +19%. Switch (NYSE:...

Shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) were crashing 26.3% lower as of 11:14 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving canc...